High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C

Hepatology

Volumn 28, Issue 4 I, 1998, Pages 1117-1120

  Ishii, Koji ^a   Rosa, Domenico ^b   Watanabe, Yushiro ^c   Katayama, Tohru ^d   Harada, Hideharu ^d   Wyatt, Colby ^b   Klyosawa, Kendo ^e   Aizaki, Hideki ^a   Matsuura, Yoshiharu ^a   Houghton, Michael ^f   Abrignani, Sergio ^b   Miyamura, Tatsuo ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b CHIRON VACCINES   (Italy)

^c ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d National Hospital Organization   (Japan)

^e SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ENVELOPE PROTEIN; NEUTRALIZING ANTIBODY; STRUCTURAL PROTEIN; VIRUS RNA;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; MALE; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VACCINATION; VIRUS ENVELOPE;

ADULT; AGED; ANTIBODY FORMATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; POLYMERASE CHAIN REACTION; REMISSION, SPONTANEOUS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; TIME FACTORS; VIRAL ENVELOPE PROTEINS;

EID: 17344367298     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510280429     Document Type: Article

References (23)

1. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo G. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989;321:1494-1500.
2. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-1905.
3. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, Watanabe Y, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1990;87:6547-6549.
4. Knodell RG, Conrad ME, Ginsburg AL, Bell CJ. Efficacy of prophylactic gamma-globulin in preventing non-A, non-B post-transfusion hepatitis. Lancet 1976;1:557-561.
5. Piazza M, Sagliocca L, Tosone G, Guadagnino V, Stazi MA, Orlando R, Borgia G, et al. Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Arch Intern Med 1997;157:1537-1544.
6. Sanchez-Quijano A, Pienda JA, Lissen E, Leal M, Diaz-Torres MA, Garcia De Pesquera F, Rivera F, et al. Prevention of post-transfusion non A, non-B hepatitis by non-specific immunoglobulin in heart surgery patients. Lancet 1988;1:1245-1249.
7. Krawczynski K, Alter MJ, Tankersley DL, Beach M, Robertson BH, Lambert S, Kuo G, et al. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 1996;173:822-828.
8. Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, Shapiro M, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 1994;91:7792-7796.
9. Choo Q-L, Kuo G, Ralston R, Weiner AJ, Chien DY, Van Nest G, Han J, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 1994;91:1294-1298.
10. Shimizu YK, Igarashi H, Kiyohara T, Cabezon T, Farci P, Purcell RH, Yoshikura H. A hyperimmune serum against a synthetic .peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology 1996;223:409-412.
11. Rosa D, Campagnoli S, Moretto C, Guenzi E, Cousens L, Chin M, Dong C, et al. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci USA 1996;93:1759-1763.
12. Miyamura T, Saito I, Katayama T, Kikuchi S, Tateda A, Houghton M, Choo QL, et al. Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA: application to diagnosis and blood screening for posttransfusion hepatitis. Proc Natl Acad Sci USA 1990;87:983-987.
13. Chiba J, Ohba H, Matsuura Y, Watanabe Y, Katayama T, Kikuchi S, Saito T, et al. Serodiagnosis of hepatitis C virus (HCV) infection with an HCV core protein molecularly expressed by a recombinant baculovirus. Proc Natl Acad Sci USA 1991;88:4641-4645.
14. Ralston R, Thudium K, Berger K, Kuo C, Gervase B, Hall J, Selby M, et al. Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. J Virol 1993;67:6753-6761.
15. Matsuura Y, Harada S, Suzuki R, Watanabe Y, Inoue Y, Saito I, Miyamura T. Expression of processed envelope protein of hepatitis C virus in mammalian and insect cells. J Virol 1992;66:1425-1431.
16. Harada S, Suzuki R, Ando A, Watanabe Y, Yagi S, Miyamura T, Saito I. Establishment of a cell line constitutively expressing E2 glycoprotein of hepatitis C virus and humoral response of hepatitis C patients to the expressed protein. J Gen Virol 1995;76:1223-1231.
17. Makimura M, Miyake S, Akino N, Takamori K, Matsuura Y, Miyamura T, Saito I. Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus. Vaccine 1996;14:28-34.
18. Aizaki H, Saito A, Kusakawa I, Ashiwara Y, Nagamori S, Toda G, Suzuki T, et al. Mother to child transmission of a hepatitis C virus variant with an insertional mutation in its hypervariable region. J Hepatol 1996;25:608-613.
19. Okamoto H, Okada S, Sugiyama Y, Yotsumoto S, Tanaka T, Yoshizawa H, Tsuda F, et al. The 5′-terminal sequence of the hepatitis C virus genome. Jpn J Exp Med 1990;60:167-177.
20. Hino K, Okuda M, Konishi T, Ishiko H, Okita K. Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-a therapy. Dig Dis Sci 1995;40:14-20.
21. Zibert A, Meisel H, Kraas W, Schulz A, Jung G, Roggendorf M. Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. HEPATOLOGY 1997;25:1245-1249.
22. Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC, Eichenlaub D, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995;346:1006-1007.
23. Botarelli P, Brunetto MR, Minutello MA, Calvo P, Unutmaz D, Weiner AJ, Choo QL, et al. T-Lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993;104:580-587.